Compare
InMed Pharmaceuticals Inc. vs BullFrog AI Holdings, Inc. vs Lexaria Bioscience Corp. vs International Stem Cell Corp
| Latest fiscal year | InMed Pharmaceuticals Inc. MTRI | BullFrog AI Holdings, Inc. BFRG | Lexaria Bioscience Corp. LEXX | International Stem Cell Corp ISCO |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-08-31 | 2025-12-31 |
| Revenue | n/a | $116.7K | $705.9K | $9.10M |
| Revenue growth (YoY) | n/a | n/a | +52.0% | +0.2% |
| Gross margin | n/a | 18.8% | 99.6% | 55.7% (computed) |
| Operating margin | n/a | n/m | n/m | -2.9% |
| Net margin | n/a | n/m | n/m | -4.6% |
| Net income | -$12.56M | -$6.50M | -$11.90M | -$418.0K |
| EPS (Diluted) | -$3.12 | -$0.63 | -$0.66 | -$0.05 |
| Operating cash flow | -$8.64M | -$5.52M | -$10.45M | $8.0K |
| Free cash flow | n/a | n/a | -$10.48M | -$35.0K |
| Cash & equivalents | n/a | $2.18M | n/a | n/a |
| Total assets | $3.03M | $2.81M | $4.18M | $4.82M |
| Total liabilities | $1.96M | $672.0K | $1.57M | $4.58M |
| Shareholders' equity | $1.08M | $2.14M | $2.99M | -$4.06M |
| Return on year-end equity | n/m | -304.2% | -398.1% | n/a |
| Shares outstanding | 5.34M | 11.42M | 19.56M | 8.00M |
Revenue, most recent five fiscal years
| Fiscal year | InMed Pharmaceuticals Inc. | BullFrog AI Holdings, Inc. | Lexaria Bioscience Corp. | International Stem Cell Corp |
|---|---|---|---|---|
| Latest | $4.94M Ended 2025-06-30 | $116.7K Ended 2025-12-31 | $705.9K Ended 2025-08-31 | $9.10M Ended 2025-12-31 |
| 1 year earlier | $4.60M Ended 2024-06-30 | n/a | $464.3K Ended 2024-08-31 | $9.09M Ended 2024-12-31 |
| 2 years earlier | $4.14M Ended 2023-06-30 | $65.0K Ended 2023-12-31 | $226.2K Ended 2023-08-31 | $7.79M Ended 2023-12-31 |
| 3 years earlier | $1.09M Ended 2022-06-30 | $10.0K Ended 2022-12-31 | $255.4K Ended 2022-08-31 | $8.18M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $722.7K Ended 2021-08-31 | $7.18M Ended 2021-12-31 |